These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8674654)

  • 1. Effects of glutamate antagonists on nigral dopamine release in the reserpine-treated rat.
    Biggs C; Starr M; Fowler L; Whitton P
    Biochem Soc Trans; 1996 Feb; 24(1):173-7. PubMed ID: 8674654
    [No Abstract]   [Full Text] [Related]  

  • 2. NMDA receptor antagonists increase the release of dopamine in the substantia nigra of reserpine-treated rats.
    Biggs CS; Fowler LJ; Whitton PS; Starr MS
    Eur J Pharmacol; 1996 Mar; 299(1-3):83-91. PubMed ID: 8901010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
    Huang KX; Bergstrom DA; Ruskin DN; Walters JR
    Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid development of dopaminergic supersensitivity in reserpine-treated rats demonstrated with 14C-2-deoxyglucose autoradiography.
    Trugman JM; James CL
    J Neurosci; 1992 Jul; 12(7):2875-9. PubMed ID: 1613560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why does clozapine stimulate the motor activity of reserpine-pretreated rats when combined with a dopamine D1 receptor agonist?
    Jackson DM; Mohell N; Bengtsson A; Malmberg A
    Eur J Pharmacol; 1995 Aug; 282(1-3):137-44. PubMed ID: 7498268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists.
    Okamura H; Murakami T; Yokoyama C; Nakamura T; Ibata Y
    J Pharmacol Exp Ther; 1997 Feb; 280(2):1031-7. PubMed ID: 9023320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
    Mela F; Marti M; Bido S; Cenci MA; Morari M
    Neurobiol Dis; 2012 Jan; 45(1):573-82. PubMed ID: 22001605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior.
    Boldry RC; Papa SM; Kask AM; Chase TN
    Brain Res; 1995 Sep; 692(1-2):259-64. PubMed ID: 8548312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
    Biggs CS; Fisher A; Starr MS
    Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    Eur J Pharmacol; 2000 Nov; 407(3):281-91. PubMed ID: 11068024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of dopamine storage, but not of dopamine synthesis, prevents activation of a tolbutamide-sensitive K+ channel in the guinea-pig substantia nigra.
    McGroarty A; Greenfield SA
    Exp Brain Res; 1996 Aug; 110(3):360-6. PubMed ID: 8871095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The release of acetylcholinesterase in vivo is regulated by dopaminergic systems in the guinea-pig substantia nigra.
    Dally JJ; Greenfield SA
    Neurochem Int; 1994 Oct; 25(4):339-44. PubMed ID: 7820067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotransformation of L-DOPA to dopamine in the substantia nigra of freely moving rats: effect of dopamine receptor agonists and antagonists.
    Sarre S; Vandeneede D; Ebinger G; Michotte Y
    J Neurochem; 1998 Apr; 70(4):1730-9. PubMed ID: 9523592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a differential medial prefrontal dopamine D1 and D2 receptor regulation of local and ventral tegmental glutamate and GABA release: a dual probe microdialysis study in the awake rat.
    Harte M; O'Connor WT
    Brain Res; 2004 Aug; 1017(1-2):120-9. PubMed ID: 15261107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors.
    Marti M; Mela F; Bianchi C; Beani L; Morari M
    J Neurochem; 2002 Nov; 83(3):635-44. PubMed ID: 12390525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX; Walters JR
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a range of dopamine receptor agonists and antagonists on ethanol intake in the rat.
    Silvestre JS; O'Neill MF; Fernandez AG; Palacios JM
    Eur J Pharmacol; 1996 Dec; 318(2-3):257-65. PubMed ID: 9016913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D1- and D2-dependent catalepsy in the rat requires functional NMDA receptors in the corpus striatum, nucleus accumbens and substantia nigra pars reticulata.
    Ozer H; Ekinci AC; Starr MS
    Brain Res; 1997 Nov; 777(1-2):51-9. PubMed ID: 9449412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
    El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
    Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.